Remove 2026 Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.

Dosage 56
article thumbnail

Cloud Computing for Pharma: The Road to Digital Transformation 

Viseven

When COVID hit, the urgent need to accelerate drug development meant shrinking timelines from years to months, with no room for compromises on quality. Cloud-based tools allowed pharma companies to capture and share clinical data between research teams both securely and quickly.